{"id":776198,"date":"2023-08-08T07:38:03","date_gmt":"2023-08-08T11:38:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/"},"modified":"2023-08-08T07:38:03","modified_gmt":"2023-08-08T11:38:03","slug":"monopar-provides-encouraging-camsirubicin-clinical-data-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/","title":{"rendered":"Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WILMETTE, Ill., Aug.  08, 2023  (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR),\u00a0a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer,\u00a0today\u00a0provided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Both patients treated to date at the 650 mg\/m<sup>2<\/sup> dose level have experienced tumor size reductions \u2013 of 18% and 20% respectively \u2013 after the first two cycles of camsirubicin treatment. Both patients are set to receive additional cycles of camsirubicin treatment, as well, which may result in further tumor size reduction.<\/p>\n<p>The Phase 1b clinical trial data is continuing to support Monopar\u2019s dose-response hypothesis with camsirubicin. The best response seen prior to the current 650 mg\/m<sup>2<\/sup> dose level was at the immediately prior dose level (520 mg\/m<sup>2<\/sup>), which was a 21% reduction in tumor size in a patient after receiving six cycles of camsirubicin treatment. This patient\u2019s cancer was unresectable at study entry, but after the tumor size reduction, became eligible and the patient underwent successful surgical removal of their cancer with clear margins. Furthermore, all three patients at the 520 mg\/m<sup>2<\/sup> dose level achieved stable disease and had either a net reduction or no overall change in tumor size per RECIST 1.1 while on study drug.<\/p>\n<p>Additionally, no drug\u00adrelated cardiotoxicity has been observed in the trial to date as evaluated by the industry standard left ventricular ejection fraction (LVEF), and no toxicities have been experienced by any patient that have required expanding the size of a dose cohort. Further, 71% of camsirubicin patients have experienced no hair loss, and only approximately 14% have experienced &gt;50% hair loss, with the remainder having low grade hair loss. This compares favorably to the approximately 50% of doxorubicin treated patients in recent ASTS clinical trials reporting some amount of hair loss, with the majority of these patients experiencing &gt;50% hair loss. Only 14% of camsirubicin patients in the Phase 1b trial have experienced mild-to-severe oral mucositis. This compares favorably to the roughly 35-40% of doxorubicin-treated patients in recent ASTS clinical trials that experienced mild-to-severe oral mucositis.<\/p>\n<p>ASTS is a deadly cancer with inadequate treatment options. Doxorubicin is currently the first-line standard of care treatment for most types of ASTS, and the average life expectancy from time of diagnosis for these patients is only about 12 to 15 months. Because of the risk of irreversible heart damage, patients discontinue doxorubicin treatment after just 6 to 8 cycles. Camsirubicin has been designed to retain the anti-cancer activity while avoiding the irreversible heart damage that is seen with doxorubicin. The value-driving hypothesis for camsirubicin is straightforward: modifying doxorubicin in order to reduce cardiac damage could enable higher and longer dosing, resulting in better efficacy and patient outcomes.<\/p>\n<p>\n        <strong>Camsirubicin Clinical Trial Design and GEIS Collaboration<\/strong>\n      <\/p>\n<p>The purpose of this dose escalation Phase 1b trial is to determine the maximum tolerated dose (MTD) of camsirubicin. Once the MTD is reached, Monopar has a clinical collaboration agreement in place with the Spanish Sarcoma Group (Grupo Espa\u00f1ol de Investigaci\u00f3n en Sarcomas, or GEIS) to conduct a multi-country randomized Phase 2 clinical trial. The Phase 2 plan is to evaluate camsirubicin head-to-head against doxorubicin in patients with ASTS, with GEIS as the study sponsor with support from Monopar.<\/p>\n<p>Further information about this actively enrolling, open-label, dose-escalation Phase 1b clinical trial is available at www.ClinicalTrials.gov under study identifier <strong>NCT 05043649<\/strong>.<\/p>\n<p>\n        <strong>About\u00a0Monopar\u00a0Therapeutics\u00a0Inc.\u00a0\u00a0<\/strong><\/p>\n<p>Monopar Therapeutics is a clinical\u00adstage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar&#8217;s pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma\u037e MNPR\u00ad101, a late\u00adstage preclinical antibody for radiopharmaceutical use in advanced cancers\u037e and MNPR\u00ad202, an early\u00adstage camsirubicin analog for various cancers. For more information, visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nvEXdheCULWihfZCYRRkAKdWnuUggl8iExbEhIAelJsSfFt6lupb-7Zwga6MHZmHT_y4SAs9CZ_694tCM7DIOUam4eKfmYsmA6pYI9qxk_bYCPQvA13E1JqeGQr6cZAmzRXCpO4bWWA-JyEOlBUNi7RbhpPk-MeNQSQAxAex-hN6PAOuBhvmbGSYUMYWfaxy6-nXzXosFmMDtCm1I8lyUl3eEuTFdy0FJihUqPcRfxA=\" rel=\"nofollow noopener\" target=\"_blank\">www.monopartx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p>Statements contained in this press release regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: that additional cycles of camsirubicin treatment may result in further tumor size reduction; that the hypothesis for camsirubicin is straightforward: modifying doxorubicin in order to reduce cardiac damage could enable higher and longer dosing, resulting in better efficacy and patient outcomes; and Monopar\u2019s plans to conduct a multi-country randomized Phase 2 clinical trial once the MTD is reached evaluating camsirubicin head-to-head against doxorubicin in patients with ASTS, with GEIS as the study sponsor with support from Monopar. The forward-looking statements involve risks and uncertainties including, but not limited to: the camsirubicin Phase 1b trial not proving safety and efficacy at higher doses; not successfully recruiting additional patients and initiating additional clinical trial sites for the camsirubicin Phase 1b clinical trial within expected timeframes, if at all; the Company\u2019s inability to raise sufficient funds or engage a partner to continue the camsirubicin clinical program beyond the Phase 1b clinical trial; GEIS not conducting the camsirubicin Phase 2 clinical trial; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar&#8217;s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar\u2019s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.<\/p>\n<p>\n        <strong>CONTACT:<\/strong>\u202f\u202f\u00a0<\/p>\n<p>\n        <strong>Monopar Therapeutics Inc.<\/strong>\u00a0<br \/>Investor Relations\u202f\u202f\u00a0<br \/>Kim R. Tsuchimoto\u202f\u202f\u00a0<br \/>Chief Financial Officer\u202f\u202f\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V_E8uN67knVoOcxv0uoLYF64r_AmuPikGI7wg5f158pO8KYC1uSP-NayNDyReUfLmedUOX5-0c7APcScugwN_mRyQamAtfRt4edsZdM6gZI=\" rel=\"nofollow noopener\" target=\"_blank\"><u>kimtsu@monopartx.com<\/u><\/a>\u00a0<\/p>\n<p>Follow Monopar on social media for updates:\u202f\u00a0<br \/>Twitter:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_4-cWk9Ef92maqSFAGkFtZMmkFDEDfBBnglJy30uGOCPCndo1T4jhkOMB_Zr0pDgqrgkrPlxpI3dxpzltgsGRw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>@MonoparTx<\/u><\/a>\u202f LinkedIn:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LvE4STA07ZAwW8p3luYAYRliMtEP7eSRZpE6W-G4Ky-YEMRZQa6_9VybA4Emcna7gKFf9GdRqrlR75tK4zJLvcs2i5Mw9nIP-gsGpM8Dldbx7P62YSSxyizZbSOwCvkpcq754IwM3V1WoW_LLtF-4A==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Monopar Therapeutics<\/u><\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4OTAzMyM1NzQxNzkxIzIxOTM4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Mjc5OTExN2QtZGQwZC00YTgxLTk3OGUtMzA0ZDk0MmY4YjU1LTEyMDU0MTY=\/tiny\/Monopar-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR),\u00a0a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer,\u00a0today\u00a0provided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Both patients treated to date at the 650 mg\/m2 dose level have experienced tumor size reductions \u2013 of 18% and 20% respectively \u2013 after the first two cycles of camsirubicin treatment. Both patients are set to receive additional cycles of camsirubicin treatment, as well, which may result in further tumor size reduction. The Phase 1b clinical trial data is continuing to support Monopar\u2019s dose-response hypothesis with camsirubicin. The best response seen prior to the current &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-776198","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR),\u00a0a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer,\u00a0today\u00a0provided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Both patients treated to date at the 650 mg\/m2 dose level have experienced tumor size reductions \u2013 of 18% and 20% respectively \u2013 after the first two cycles of camsirubicin treatment. Both patients are set to receive additional cycles of camsirubicin treatment, as well, which may result in further tumor size reduction. The Phase 1b clinical trial data is continuing to support Monopar\u2019s dose-response hypothesis with camsirubicin. The best response seen prior to the current &hellip; Continue reading &quot;Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-08T11:38:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4OTAzMyM1NzQxNzkxIzIxOTM4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-provides-encouraging-camsirubicin-clinical-data-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-provides-encouraging-camsirubicin-clinical-data-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update\",\"datePublished\":\"2023-08-08T11:38:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-provides-encouraging-camsirubicin-clinical-data-update\\\/\"},\"wordCount\":1006,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-provides-encouraging-camsirubicin-clinical-data-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4OTAzMyM1NzQxNzkxIzIxOTM4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-provides-encouraging-camsirubicin-clinical-data-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-provides-encouraging-camsirubicin-clinical-data-update\\\/\",\"name\":\"Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-provides-encouraging-camsirubicin-clinical-data-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-provides-encouraging-camsirubicin-clinical-data-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4OTAzMyM1NzQxNzkxIzIxOTM4NjM=\",\"datePublished\":\"2023-08-08T11:38:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-provides-encouraging-camsirubicin-clinical-data-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-provides-encouraging-camsirubicin-clinical-data-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-provides-encouraging-camsirubicin-clinical-data-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4OTAzMyM1NzQxNzkxIzIxOTM4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4OTAzMyM1NzQxNzkxIzIxOTM4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-provides-encouraging-camsirubicin-clinical-data-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/","og_locale":"en_US","og_type":"article","og_title":"Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update - Market Newsdesk","og_description":"WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR),\u00a0a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer,\u00a0today\u00a0provided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Both patients treated to date at the 650 mg\/m2 dose level have experienced tumor size reductions \u2013 of 18% and 20% respectively \u2013 after the first two cycles of camsirubicin treatment. Both patients are set to receive additional cycles of camsirubicin treatment, as well, which may result in further tumor size reduction. The Phase 1b clinical trial data is continuing to support Monopar\u2019s dose-response hypothesis with camsirubicin. The best response seen prior to the current &hellip; Continue reading \"Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-08T11:38:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4OTAzMyM1NzQxNzkxIzIxOTM4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update","datePublished":"2023-08-08T11:38:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/"},"wordCount":1006,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4OTAzMyM1NzQxNzkxIzIxOTM4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/","name":"Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4OTAzMyM1NzQxNzkxIzIxOTM4NjM=","datePublished":"2023-08-08T11:38:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4OTAzMyM1NzQxNzkxIzIxOTM4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4OTAzMyM1NzQxNzkxIzIxOTM4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-provides-encouraging-camsirubicin-clinical-data-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Monopar\u00a0Provides Encouraging Camsirubicin Clinical Data Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/776198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=776198"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/776198\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=776198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=776198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=776198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}